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ABSTRACT
Objectives: To determine the efficacy of ornithine-aspartate in reducing blood ammonia levels and clinical
improvement, as a part of treatment in hepatic encephalopathy. Material & method: A randomized placebo controlled
trial was conducted in 2013 in Jinnah medical and dental college hospital Korangi Karachi. One hundred patients with
hepatic encephalopathy due to underlying chronic liver disease were randomly assigned into two groups with 50
patients each. One group received three days of ornithine-aspartate infusions (trial-treatment group) and the other
group received three days of infusion of placebo (placebo group). Serum ammonia was measured in both groups on
day 1 and day 3. Clinical improvement was assessed by West Haven’s grading of hepatic encephalopathy. Result: The
patients in trial group showed statistically significant improvement in serum ammonia levels and grading of hepatic
encephalopathy as compared to placebo. Conclusion: L -Ornithinie L-Aspartate (LOLA) is effective in decreasing serum
ammonia as well as results in clinical improvement in patients with hepatic encephalopathy and may be recommended
for use in hepatic encephalopathy.
KEY WORDS: Hepatic Encephalopathy, Chronic Liver Disease, Serum Ammonia, Ornithine-Aspartate.
INTRODUCTION

conditions associated with excess ammonia
(constipation, protein overload, internal bleeding or
sepsis).5 It also explains the reason why some patients
have marginal elevation of arterial ammonia, despite
hepatic encephalopathy.6 Therefore reduction in
ammonia levels in the body is important treatment
strategy.7 The L-ornithine L-Aspartate(LOLA) are salts of
naturally occurring aminoacids ornithine and aspartate.
They stimulate urea cycle and glutamine synthesis,
which are major mechanisms of ammonia detoxification.8
Over last 25 years, various studies were carried out
regarding efficacy of LOLA in improvement of hepatic
encephalopathy, showed controversial results. Blanco
et al compared the standard treatment, with LOLA and
concluded that LOLA was effective not only in reducing
hyperammonemia and the severity of this disease, but
also in improving the patient's perceived quality of life.9
Sharma et al conducted a study in 2014and concluded
that LOLA, probiotics and rifxamine were all superior to
placebo, although this study was conducted on patients
with minimal hepatic encephalopathy.10 A meta-analysis
done in 2009 reviewed four studies and concluded that
although use of LOLA was associated with decreasing
serum ammonia levels, no clinical improvement was

Cirrhosis or end stage liver disease is destruction of
normal liver parenchyma, replaced by regenerating
nodules and scar tissue, due to various reasons
common causes includes HBV, HCV, and alcoholic liver
disease. Hepatic Encephalopathy is present in about
50-70% of all patients with cirrhosis.(1) Hepatic
Encephalopathy is a complex neuropsychiatric syndrome
associated with acute or chronic hepato- cellular failure
and porto-systemic shunting of blood. It is one of the
major complications of cirrhosis. Various neurotoxins
have been known to involve in pathogenesis of hepatic
encephalopathy. High levels of ammonia, glutamate,
endogenous benzodiazepines, Gamma Amino butyric
Acid (GABA) have been strongly associated with acute
hepatic encephalopathy. 2 Among these, raised level of
ammonia is thought to play a major role in pathogenesis
of hepatic encephalopathy. 3,4 In hepatic encephalopathy the rate of ammonia metabolism decreases and its
permeability to blood brain barrier increases, resulting
in elevated ammonia levels in brain with variable
changes in blood. This mechanism is also supported by
the fact that cirrhotic patients are sensitive to

PAKISTAN JOURNAL OF NEUROLOGICAL SCIENCES

37

VOL. 10 (3) JUL

-

SEPT

2015

imbalance, prolonged prothrombin time were treated
accordingly. Performa was completed for each patient
to record demographics, vitals, complete blood counts,
liver function tests, prothrombin time, total proteins,
electrolytes, serum ammonia, random blood glucose
and renal status. In addition, ultra-sound of the whole
abdomen was also done, to assess the size of liver,
spleen and portal vein. Trial-Treatment group received a
daily intravenous infusion of 20 g (4 ampoules)
L-Ornithine L-Aspartate (Inj HepaMerz, Brooks pharma)
diluted in 250 ml of 5% dextrose water administered
slowly over 4 hours for three consecutive days. The
Placebo group received a daily administration of 250 ml
normal saline over 4 hours for three consecutive days.
It was ensured that the infusions were given at the
same specified time to both groups of patients. About 5
ml of blood of each patient was drawn on Day 1 and
Day 3 under aseptic techniques, stored in rubber
corked glass tubes for checking ammonia levels. The
Tubes were frozen at 4 degrees centigrade temperature.
The ammonia determination was performed according
to the enzymatic determination of ammonia with
glutamine dehydrogenase in a rapid and interference –
free photomertric determination of NH4+ in native
blood plasma. The testing was performed at a reliable
laboratory of Karachi. Sample on Day 1, was collected
as soon as a patient presented, before any treatment
was started. The second sample was drawn on Day 3
i.e. after the patient received three days of the
Trial-Treatment or Placebo. Clinical improvement in
hepatic encephalopathy was noted by West Haven’s
criteria, on day 1 before LOLA infusion and on day III
after infusion. Data was collected on the prescribed
performa and analyzed using Statistical Package for
Social Services (SPSS) V 17. Numerical data was
recorded as mean and standard deviation, nominal data
was recorded as frequency and percentage. Patients on
treatment with Ornithine - Aspartate infusion and on
placebo were compared by paired t-test. A p-value of <
0.05 was considered statistically significant.

observed. But these studies were of small sample size
and shorter follow ups.11 Another meta-analysis done
on three studies showed that LOLA therapy causes
decrease in serum ammonia levels, and also clinical
improvement.12 Moreover most of the available data
assessed role of LOLA in minimal encephalopathy, not
the over encephalopathy. In the review of local data,
there are only two authentic large trials available.13,14
Therefore due to absence of large studies, controversial
existing data and paucity of local data, we conducted a
study to observe effect of LOLA on clinical improvement
in most stages of hepatic encephalopathy.
MATERIAL & METHOD
After approval of Ethical review committee of Jinnah
Medical and Dental College, a randomized, placebocontrol trial was performed in medical department of
Jinnah medical and dental college Hospital Korangi
Karachi from July 2013 to June 2014. The trial was
designed and reported according to CONSORT
guidelines.15 An informed consent was taken before
entry in the trial. Data was collected by Interns and
residents of the ward, who were trained by the authors
for this study through workshops and meetings.
Patients > 18 years of age, admitted in medical ward,
diagnosed with Chronic liver disease (CLD) due to any
cause, having grade II to grade IV Hepatic
Encephalopathy were included in the study after
informed consent. CLD was diagnosed by common
complications like ascites, gastro-oesophagal varices,
with sonographic findings of shrunken liver, splenomegaly,
portal vein size > 1 cm, deranged clotting profile and
and inverse albumin /globulin ratio. Hepatic
encephalopathy was diagnosed on the basis of
confusion, drowsiness, restlessness, disorientation and
asterixis without any altered explanation of these
symptoms. Clinical grading of hepatic encephalopathy
was done by West Haven’s criteria.16 Patient having
sepsis, hepatorenal syndrome, acute/ chronic kidney
disease were excluded from the study because they
might affect ammonia levels. Hypoglycemia and
respiratory failure was excluded by measuring random
blood sugar and arterial blood gases. The estimated
sample size was 102 patients, considering 500 annual
admissions in our ward. The patients meeting inclusion
criteria were randomly allocated into two groups with 50
patients in each group. The Trial-Treatment group
received L-Ornithine L-Aspartate; the Placebo group
received normal saline. Both groups continued to
receive all other standard supportive treatment
including lactulose and metronidazole. The patients
with precipitating factors such as infection,
constipation, hypokalemia, dehydration, electrolyte
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RESULT
Out of 102, two patients were discharged or referred
before collection of data. The remaining patients
completed study. Half of the patients (50), received
L-Ornithine L-Aspartate (LOLA) and half received Placebo
(50). In LOLA group 20(40%) were female and 30(60%)
were male. In placebo group were 22(44%) female and
28(56%) male. Mean age was 49.66+ 12.25 SD in trial
group and 46.06 +9.83 SD in placebo group. Out of 100
people 43 % had HCV, 22 % had HBV, 4 % were non B-C
and 8 % had both B and C virus. (Table: I) On Day I mean
ammonia was 105.2 micromol/l in trial group. (Normal
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range: 6-47 micromol/l). In placebo group mean
ammonia level was 112.28 micromole /dl on Day
I.(Table:II) On Day III mean ammonia level in the trial
group was 74.16 micromol/L. In placebo group mean
ammonia level was 110.52 micromol/L .On comparison of
serum ammonia levels before(day 1) and after (day 3)
L-ornithine L aspartate therapy ,the difference was
statistically significant in trial group(p value 0.0013) while
it was non significant in placebo group.(p value 0.124)
(Table : II) To assess clinical improvement with LOLA, we
used clinical grading of hepatic encephalopathy. In trial
group, On Day I 10(20%) were in grade II, 17(34%) were
in grade III and 23(46%) were in grade IV hepatic
encephalopathy, while on day III 4(8%) were in grade
zero, 18(36%) were in I, 20(40% ) were in grade II,
8(16%) in grade III and zero were in grade IV hepatic
encephalopathy. (Table:III) In placebo group on day I
12(24%) % were in grade II, 19(38%) were in grade III,
19(38%) were in grade IV hepatic encephalopathy, while
on day III no patient % was in grade zero,10(20%) were in
grade I, 12 (24%) were in grade II, 18(36%) were in
grade III and 10(20%) were in grade IV hepatic
encephalopathy. On Day I clinical difference in grading of
hepatic encephalopathy between two groups was
statistically non significant. (p-values > 0.05) while on
Day III, significant clinical improvement was observed p
value < 0.05.(Table: III)

to identify two clinical trials. In 2011 Abid et al conducted
a study in Agha Khan university Hospital on 110 patients
concluded that LOLA was safe and associated with rapid
clinical improvement and shorter hospital stay.14 Ahmed et
al conducted a study in in Shaikh Zyed hospital Lahore on
80 patients in 2008 concluded that ornithine infusion
was associated with rapid clinical recovery and decrease
serum ammonia.13 Considering the results of our trial and
other national and international studies and meta
analysis, we can recommend use of LOLA as addition to
other standard therapies of hepatic encephalopathy since
ornithine therapy is safe, with mild side effects like
nausea and vomiting and is easily available, can be given
both orally and parenterally and does not adds significant
cost to treatment of hepatic encephalopathy. Future
studies should be directed towards comparison of
efficacy L ornithine therapy with others drugs used for
standard treatment of hepatic encephalopathy like
lactitol, rifixamine, Zinc supplements and branch chain
amino acids.
CONCLUSION
LOLA is effective in decreasing serum ammonia as well
as causes clinical improvement in patients with hepatic
encephalopathy. It can be recommended that LOLA
may be used in the patients with hepatic
encephalopathy especially when not responsive to
standard treatment regimen.

DISCUSSION

Table I: Distribution
characteristics

In developing countries like Pakistan cirrhosis liver is more
prevalent compared to developed countries.17 In fact both
hepatitis B virus (HBV) and hepatitis C virus (HCV)
infections have become endemic in our community.18,19
Hepatic Encephalopathy is a common neuro-psychiatric
complication in CLD. High levels of ammonia in the body
is a major cause of hepatic encephalopathy, that’s why
most of the treatments are targeted against the
detoxification of ammonia. L Ornithine L aspartate (LOLA)
stimulates the urea cycle and ammonia utilization that’s
why thought to be useful in acute hepatic encephalopathy.
In our study, it was observed that the LOLA has beneficial
effects not only in clinical improvement of encephalopathy
but also obvious decrease in serum ammonia levels after
infusion of LOLA. These results were comparable to other
studies. Bai et al concluded after meta-analysis of 8
randomized clinical trials including 646 patients that,
LOLA was beneficial in both overt and minimal hepatic
encephalopathy, causes both clinical and biochemical
detoxification of ammonia.20 Another meta analysis done
in 2011 supported the use of LOLA for neuro-psychiatric
improvement as well as decreasing levels of ammonia.21
Although regional data is sparse however, it is necessary
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Characters
Age
Male
Female
Child-Pugh
class A
Child-Pugh
class B
Child-Pugh
class- C
Patients having
HBV
Patients having
HCV
Patient having
Non-B/C CLD
Patients with
both B/C CLD
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of

patients

according

to

Trial group n= 50
49.66+ 12.25
30 (60%)
20(40%)
3(6%)

Placebogroup n=50
46.04 + 9.837
28(56%)
22(44%)
zero

17(34%)

21(42%)

29(58%)

29(58%)

12(24%)

10(20%)

35(70%)

33(66%)

________

2(4%)

3(6%)

5(10%)

SEPT

2015

TABLE II: Distribution of patients according to mean
serum ammonia levels on Day I and Day III:
Day I
105.24
112.28

Trial group
Placebo group

Day III
74.16
110.52

7.

p-values
0.0013
0.124

TABLE III : Distribution of patients according to grades
of Hepatic encephalopathy on Day I & III:
DAY I
Grade II
Grade III
Grade IV
DAY III
Grade zero
Grade I
Grade II
Grade III
Grade IV

Trial group
10(20%)
17(34%)
23(46%)

Placebo Group
12(24%)
19(38%)
19(38%)

4(8%)
18(36%)
20(40%)
8(16%)
----

-----10(20%)
12(24%)
18(36%)
10(20%)

8.

P values
0.652
0.648
0.324

9.
0.0345
0.0384
0.0467

10.
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